MedPath

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Phase 1
Completed
Conditions
Schizophrenia
Registration Number
NCT00805454
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.

Detailed Description

Subjects will receive a dose of study medication and will undergo a PET scan at 4 hrs and 23.5 hours post dose. Subjects will remain in the clinic from Day-1 to Day 7 for PK sample collection and safety monitoring. Subjects will return to the clinic on Day 10 for a follow-up safety assessment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Males and non-child bearing potential females between 18 and 45 years of age, inclusive.
  • BMI between 19 and 32 kg/m2, inclusive.
Exclusion Criteria
  • Condition or history which may present a safety concern to the subject or interfere with outcome variables.
  • History of or current drug or alcohol abuse, hepatitis, AIDS, or drug allergy.
  • Use of prescription, over-the-counter, or herbal medication, or vitamin supplements within 14 days or antibiotics within 30 days.
  • Use of tobacco products or daily exposue to second hand smoke.
  • Blood pressure higher than 140/90 mmHg or lower than 100/50 mmHg: heart rate outside 40 to 90 beats/minute.
  • History of serious mental disorder.

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pharmacodynamic: Percent occupancy of D2 receptor, as judged by PET scan.10 days
Secondary Outcome Measures
NameTimeMethod
Measure safety: adverse events, vital signs, ECGs, and clinical laboratory tests30 days
© Copyright 2025. All Rights Reserved by MedPath